IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R.
Maloney DG, et al. Among authors: bodkin d.
Blood. 1997 Sep 15;90(6):2188-95.
Blood. 1997.
PMID: 9310469
Free article.
Clinical Trial.